TRAVAGLINI, DANIELA
 Distribuzione geografica
Continente #
NA - Nord America 686
EU - Europa 591
AS - Asia 305
Continente sconosciuto - Info sul continente non disponibili 3
Totale 1.585
Nazione #
US - Stati Uniti d'America 686
CN - Cina 178
IE - Irlanda 116
UA - Ucraina 107
SE - Svezia 90
GB - Regno Unito 86
TR - Turchia 84
IT - Italia 62
FR - Francia 52
DE - Germania 46
IN - India 32
FI - Finlandia 25
IR - Iran 4
EU - Europa 3
BE - Belgio 2
GR - Grecia 2
KR - Corea 2
SG - Singapore 2
CZ - Repubblica Ceca 1
DK - Danimarca 1
IL - Israele 1
PH - Filippine 1
RU - Federazione Russa 1
TW - Taiwan 1
Totale 1.585
Città #
Chandler 152
Jacksonville 144
Dublin 116
Southend 80
Ashburn 54
Princeton 52
Nanjing 50
Beijing 41
Izmir 39
Dearborn 26
New York 26
Cambridge 24
Nanchang 18
Wilmington 18
Altamura 16
Ann Arbor 12
Grevenbroich 12
Chieti 10
Shenyang 9
Washington 9
Norwalk 8
Torino 8
Kunming 7
Hangzhou 6
Los Angeles 6
Tianjin 6
Changchun 5
Changsha 5
Guangzhou 5
Hebei 5
Boardman 4
Jiaxing 4
Jinan 4
Lanzhou 4
Monmouth Junction 4
Ardabil 3
Augusta 3
San Mateo 3
San Vito Chietino 3
Brussels 2
Campobasso 2
Leawood 2
Mumbai 2
Ningbo 2
Redmond 2
Singapore 2
Taizhou 2
Tappahannock 2
Woodbridge 2
Zhengzhou 2
Andover 1
Bangalore 1
Capurso 1
Centrale 1
Chengdu 1
Hanover 1
Helsinki 1
London 1
Manila 1
Monte di Procida 1
Moscow 1
Mountain View 1
Olomouc 1
Orange 1
Parrano 1
Phoenix 1
Pune 1
Quanzhou 1
Rome 1
San Jose 1
San Salvo 1
Taipei 1
Walnut 1
Totale 1.046
Nome #
Cleavage of cystatin C is not associated with multiple sclerosis 98
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 83
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 82
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 81
Increasing age at disability milestones among MS patients in the MSBase Registry 76
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 76
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 71
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients 68
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 67
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 66
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 65
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 64
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 63
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 62
JCV-Ab serostatus in MS patients treated with Natalizumab 62
Natalizumab-associated PML-IRIS: the Chieti experience. 62
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 62
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 60
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 59
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 56
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 53
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 52
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis 45
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 41
New daily persistent headache after SARS-CoV-2 infection: a report of two cases 30
Totale 1.604
Categoria #
all - tutte 5.465
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.465


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201960 0 0 0 0 0 0 0 0 0 0 0 60
2019/2020324 96 24 2 2 23 26 40 32 10 29 38 2
2020/2021126 24 0 25 0 1 26 0 0 20 8 20 2
2021/2022119 0 4 6 29 5 2 10 8 10 3 13 29
2022/2023385 26 62 25 29 47 72 20 28 57 5 7 7
2023/2024212 12 9 16 3 23 111 24 0 1 6 3 4
Totale 1.604